Abstract
Background: Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an extracellularly binding FGFR inhibitor using a combined molecular modeling and de novo design strategy.
Methods: Based upon crystal structures of the receptor with its native ligand and knowledge of inhibiting peptides, we have developed a computational protocol that predicts the putative binding of a molecule to the extracellular domains of the receptor. This protocol, or scoring function, was used in combination with the de novo synthesis program 'SYNOPSIS' to generate high scoring and synthetically accessible compounds.
Results: Eight compounds belonging to 3 separate chemical classes were synthesized. One of these compounds, alofanib (RPT835), was found to be an effective inhibitor of the FGF/FGFR2 pathway. The preclinical in vitro data support an allosteric inhibition mechanism of RPT835. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L.
Conclusion: These results provide strong rationale for the evaluation of compound in advanced cancers.
Keywords: Fibroblast growth factor receptor 2, allosteric inhibitor, alofanib, RPT835.
Medicinal Chemistry
Title:Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835)
Volume: 12 Issue: 4
Author(s): Ilya Tsimafeyeu, Frits Daeyaert, Jean-Baptiste Joos, Koen V. Aken, John Ludes-Meyers, Mikhail Byakhov and Sergei Tjulandin
Affiliation:
Keywords: Fibroblast growth factor receptor 2, allosteric inhibitor, alofanib, RPT835.
Abstract: Background: Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an extracellularly binding FGFR inhibitor using a combined molecular modeling and de novo design strategy.
Methods: Based upon crystal structures of the receptor with its native ligand and knowledge of inhibiting peptides, we have developed a computational protocol that predicts the putative binding of a molecule to the extracellular domains of the receptor. This protocol, or scoring function, was used in combination with the de novo synthesis program 'SYNOPSIS' to generate high scoring and synthetically accessible compounds.
Results: Eight compounds belonging to 3 separate chemical classes were synthesized. One of these compounds, alofanib (RPT835), was found to be an effective inhibitor of the FGF/FGFR2 pathway. The preclinical in vitro data support an allosteric inhibition mechanism of RPT835. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L.
Conclusion: These results provide strong rationale for the evaluation of compound in advanced cancers.
Export Options
About this article
Cite this article as:
Tsimafeyeu Ilya, Daeyaert Frits, Joos Jean-Baptiste, Aken V. Koen, Ludes-Meyers John, Byakhov Mikhail and Tjulandin Sergei, Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835), Medicinal Chemistry 2016; 12 (4) . https://dx.doi.org/10.2174/1573406412666160106154726
DOI https://dx.doi.org/10.2174/1573406412666160106154726 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Preparation and Characterization of Bifunctional Nanoparticles of Vitamin E TPGS-emulsified PLGA-PEG-FOL Containing Deferasirox
Nanoscience & Nanotechnology-Asia Exploration of Structure-Based on Imidazole Core as Antibacterial Agents
Current Topics in Medicinal Chemistry Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy
Current Drug Targets Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Recent Patents in Glycan-Based Cancer Biomarkers and Discovery Technologies
Recent Patents on Biomarkers BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Current Medicinal Chemistry Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
Current Medicinal Chemistry Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Regulation of KRAS-PAK4 Axis by MicroRNAs in Cancer
Current Pharmaceutical Design Induction of Apoptosis via the Modulation of Reactive Oxygen Species (ROS) Production in the Treatment of Myeloid Leukemia
Current Pharmaceutical Biotechnology Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued)